| 2008-10-23: |
Sanofi - aventis is Complying With the EMEA's Recommendation to Temporarily Suspend the Marketing Authorisation of Acomplia( R ) in Obese and Overweight Patients
Paris ( PRN/ots ) - - Sanofi - aventis Will Comply With the European Authorities Request to Temporarily Suspend the Marketing Authorisation of Acomplia( R ) in Obese and Overweight Patients and Will Make Every Effort to Actively Support Patients and Health Care Professionals in This Process. - Sanofi - aventis (...) |
| 2011-01-19: |
AMP's SIVAC Initiative Supports Mozambique to Set Up its National Immunization Technical Advisory Group ( NITAG )
Paris ( PRN/ots ) - The inaugural meeting of Mozambique's Committee of Experts on Immunization ( Comité de Peritos para a Imunização, CoPI ) was held in Maputo on January 7, 2011. The CoPI is the second National Immunization Technical Advisory Group ( NITAG ) in a sub - Saharan (...) |
| 2010-06-24: |
MDS Nordion, Guerbet, and Cyceron Announce Partnership to Develop New Diagnostic Agents
Ottawa, June 24, 2010 ( PRN/ots ) - MDS Nordion, a leading provider of products and services to the global health science market, Guerbet, a pharmaceutical group specialized in medical imaging, and Cyceron, a biomedical imaging centre in France, announced today they have entered into an (...) |
| 2009-07-06: |
European Commission Approves Statement on Lipid Improvement for VIRAMUNE( R ) Label
Ingelheim, Germany ( PRN/ots ) - - For Medical Media Outside the US only Boehringer Ingelheim announced today that the European Commission has approved an update of the Summary of Product Characteristics ( SmPC ) for VIRAMUNE( R ) ( nevirapine ) in the treatment of patients with HIV. The decision (...) |
| 2006-08-02: |
Medify Solutions Limited ( Pink Sheets MFYS ) - Statement
Gateshead, England ( PRN/ots ) - Due to the number of product sales enquiries from UK based NHS GP practices, Medify Solutions Limited would like to clarify the product availability situation. The first production release of Medify Remote is scheduled to be utilised at Doncaster Central (...) |
| 2004-12-06: |
LAB International to Initiate Phase II Trial for GHRH
Laval, Canada ( PRN/ots ) - - Malnutrition in Patients With Late Pre - end - stage Chronic Renal Failure Selected as Clinical Indication for Trial LAB International Inc. ( TSX: LAB ), an integrated drug development company focused on the inhalation market, today announced that, after completion of (...) |
| 2004-10-26: |
Orion Pharma and Novartis Launch First Parkinson's Disease Study to Explore Potential of Delaying Motor Complications With Stalevo( R )
Espoo, Finland ( PRN/ots ) - - Parkinson's Patients who Require the Start of Levodopa Therapy may be Eligible to Participate in This Study Orion Pharma and Novartis announced that they are launching STRIDE - PD ( STalevo Reduction In Dyskinesia Evaluation ). This major study in Parkinson's (...) |
| 2006-12-11: |
Xeloda Meets Primary Endpoint in Multinational Phase III Advanced Colorectal Cancer Study
Basel, Switzerland ( PRN/ots ) - - Roche to Approach World - Wide Regulatory Authorities for a New File Submission Roche announced today that a large, international Phase III study ( NO16967 ) of 627 previously treated patients with advanced colorectal cancer met its primary endpoint of progression - (...) |
| 2009-03-31: |
Avastin Label Updated Reflecting Confidence in Safety Profile
Basel, Switzerland ( PRN/ots ) - - Contraindication for Patients With Untreated Brain Metastases Removed - For non - US, UK and Austrian Media Only The European Medicines Agency ( EMEA ) has removed a restriction in the product label which prevented the use of Avastin( R ) ( bevacizumab ) in some (...) |
| 2008-06-07: |
GRAZAX( R ) Demonstrates Significant Reductions on Asthma Symptoms in Children
Barcelona ( PRN/ots ) - - In Addition to Effects on Allergic Rhinitis ( Hayfever ), GRAZAX( R ) Demonstrated Significant Reductions in Asthma Symptoms in Children Aged 5 to 16 Years Old ALK - Abelló today presented successful results from a new clinical trial, GT - 12, designed to measure (...) |
| 2008-06-27: |
INTELENCE( TM ) ( etravirine ) Receives Positive Opinion From European Committee for Human Medicinal Products ( CHMP ) for Treatment of HIV
Cork, Ireland ( PRN/ots ) - - INTELENCE is the first NNRTI to demonstrate antiviral activity in patients with NNRTI - resistant virus - Tibotec Pharmaceuticals, Ltd. announced today that the Committee for Human Medicinal Products ( CHMP ) of the European Medicines Agency ( EMEA ) has issued a (...) |
| 2008-11-20: |
Intel Announces its First Home Medical Device in the United Kingdom to Better Connect Clinicians With Patients
London, November 20 ( PRN/ots ) - - Intel( R ) Health Guide is the First Product in a Series Designed to Enable More Personalised Care Management for Chronic and Age - related Conditions Intel Corporation today announced the Intel( R ) Health Guide, a care management tool designed for (...) |
| 2008-10-07: |
Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
KVISTGÅRD, Denmark, October 7 ( PRN/ots ) - - 125 Patient, Prospective Randomized Placebo - Controlled Phase II Study Shows Statistically Significant Improved Overall Survival KVISTGÅRD, Denmark, October 7 /PRNewswire/ - - Bavarian Nordic has now evaluated the mature phase II data from the therapeutic prostate cancer (...) |
| 2011-04-08: |
Amgen Establishes Commercial Operations in Brazil
Thousand Oaks, California ( PRN/ots ) - Amgen , the world's largest biotechnology company, announced today the expansion of its operations in Brazil, including the acquisition of Bergamo, a privately - held Brazilian pharmaceutical company. Amgen has also agreed to reacquire rights in Brazil to its products (...) |
| 2010-12-15: |
Agendia Publishes Compelling First Independent Validation Study of Colon Cancer Recurrence Test "ColoPrint" in Journal of Clinical Oncology
Irvine, California and Amsterdam ( PRN/ots ) - Agendia, a world leader in molecular cancer diagnostics, announced today that together with principal investigators from Spain, the UK, and the Netherlands, it has published the first independent validation study of its colon cancer recurrence test "ColoPrint" (...) |
| 2009-04-25: |
Ground - Breaking Combination of All - Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
BASEL, Switzerland, BRISBANE, California and PRINCETON, New Jersey, April 25 ( PRN/ots ) - - - Combination of R7227, Protease Inhibitor, and R7128, Nucleoside Polymerase Inhibitor, Shows Significant Potency in Reducing Viral Load in Patients With Hepatitis C Roche ( SWX: RO, ROG; OTCQX: RHHBY ), InterMune, Inc. (...) |
| 2009-07-30: |
Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation
Tainan, Taiwan ( PRN/ots ) - Eli Lilly & Company ( "Lilly" ) and ScinoPharm Taiwan Ltd. ( "ScinoPharm" ) announced today that they have reached an amicable resolution of all ongoing patent litigations between the companies relating to ScinoPharm's manufacture and sale of gemcitabine hydrochloride around the world. (...) |
| 2008-03-05: |
MIRCERA( R ) Successfully Corrects Anaemia With a Smooth and Steady Rise in Haemoglobin Levels in Line With Current Guidelines
Basel, Switzerland ( PRN/ots ) - The results of a large - scale study of patients with chronic kidney disease ( CKD ) who are not on dialysis, and who have never received a treatment for anaemia before, has found that MIRCERA given at an extended dosing interval once (...) |
| 2007-09-06: |
AstraZeneca Announces First Patient Enrolled in Head - to - Head Comparison of CRESTOR/Ezetimibe With Simvastatin/Ezetimibe
London ( PRN/ots ) - AstraZeneca today announced enrolment of the first patient in the new GRAVITY study ( Gauging the lipid effects of RosuvAstatin plus ezetimibe Versus sImvastatin plus ezetimibe TherapY ). GRAVITY is a clinical trial examining the impact on LDL - cholesterol ( 'bad' cholesterol ) levels in (...) |
| 2008-01-28: |
Many More Patients Can Now Benefit From Avastin's Proven Survival Benefits
Basel, Switzerland ( PRN/ots ) - - Avastin Receives Broad Label Extension in Europe for the Treatment of Patients With Metastatic Colorectal Cancer Roche announced today that the European Commission ( EC ) has given its approval for the significantly wider use of its anti - angiogenic agent (...) |
| 2008-11-27: |
Bacardi Limited Offers "Driving Experience of a Lifetime" With F1( TM ) Legend Michael Schumacher
Hamilton, Bermuda, November 27 ( PRN/ots ) - - Schumacher - The Ultimate Designated Driver - Promotes Drinking and Driving Don't Mix at http://www.championsdrinkresponsibly.com Bacardi Limited, as part of its responsible drinking "Champions Drink Responsibly" campaign, is providing the drive of a lifetime - the opportunity (...) |
| 2009-09-07: |
Rheumatoid Arthritis ( RA ) Patients Taking Enbrel Keep Working for Longer
Maidenhead, England ( PRN/ots ) - - Study Published in Rheumatology Underscores the Need for Early and Aggressive Treatment to Maintain Work Productivity Patients receiving Enbrel( R ) ( etanercept ) in combination with methotrexate for early RA are more likely to continue working, according to the COMET study (...) |
| 2009-07-06: |
New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects
Leiden, The Netherlands ( PRN/ots ) - Three new small and medium sized enterprises ( SMEs ) - Syncom, Synvolux Therapeutics and InteRNA Technologies - have joined public - private partnership TI Pharma by participating in two new projects. These projects, focusing on cancer and inflammatory diseases, have a total budget (...) |
| 2008-10-06: |
Botaneco Receives Natural Ingredient Approval From ECOCERT( R ) for Hydresia( TM ) G2
Calgary, Canada ( PRN/ots ) - - Hydresia( TM ) G2 Approved by leading European Authority on Natural Organic Certification TSX symbol: SBS Botaneco Specialty Ingredients Inc. ( Botaneco ), a subsidiary of SemBioSys Genetics Inc. ( SemBioSys ), today announced that its second generation oleosome product, Hydresia( TM ) G2, has been (...) |
| 2007-08-01: |
Eslax( R ) ( Rocuronium Bromide ) Approved in Japan
Oss, The Netherlands ( PRN/ots ) - Organon, the human healthcare business unit of Akzo Nobel ( Euronext Amsterdam: AKZ ), today announced that the Japanese Ministry of Health, Labour and Welfare ( MHLW ) has approved rocuronium bromide, its neuromuscular blocking agent ( NMBA ) for use during general anesthesia, under (...) |
| 2008-02-04: |
Promising Phase 3 Data for Ustekinumab ( CNTO 1275 ) in Long - Term Improvement of Chronic Plaque Psoriasis
San Antonio, Texas ( PRN/ots ) - - New Findings From a Second Pivotal Phase 3 Study Show Subjects Receiving Ustekinumab Every 12 weeks Maintained Improvement From Psoriasis Through One Year One - year data from the second double blind, placebo - controlled Phase 3 study PHOENIX (...) |
| 2009-02-19: |
CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Collegeville, Pennsylvania ( PRN/ots ) - The Committee for Medicinal Products for Human Use ( CHMP ), the scientific committee of the European Medicines Agency ( EMEA ), today adopted a positive opinion recommending to grant a marketing authorization for CONBRIZA( TM ) ( bazedoxifene ) for the treatment of postmenopausal osteoporosis in (...) |
| 2007-07-10: |
Macrochem Acquires Option To License Pexiganan, a Novel Topical Anti - Infective for Treatment of Diabetic Foot Infection, from Genaera
Wellesley Hills, Massachusetts ( PRN/ots ) - - Broadens late - stage product development portfolio building on lead product candidate EcoNail in Phase 2 trial for onychomycosis MacroChem Corporation ( OTCBB: MACM ) today announced that it has signed an exclusive option to acquire exclusive worldwide license rights (...) |
| 2005-12-09: |
New Data Show Survival Benefit for Arimidex( TM ) in Early Breast Cancer
Macclesfield, England ( PRN/ots ) - - Replacing tamoxifen With Arimidex ( TM ) ( anastrozole ) Shown to Reduce Patient's Risk of Death by Nearly a Third Breakthrough new data presented today show breast cancer treatment 'Arimidex' ( anastrozole ) is the first aromatase inhibitor ( AI ) to provide an overall (...) |
| 2010-07-06: |
Pfizer Announces European Union Approval of a New Form of Lipitor ( atorvastatin ) for Use in Children
New York, July 6, 2010 ( PRN/ots ) - Pfizer Inc. announced it has received European Commission approval of a new chewable form of Lipitor ( atorvastatin calcium ) suitable for use in children aged 10 or older with high levels of LDL ( "bad" ) cholesterol and high triglycerides (...) |
| 2008-11-07: |
Media Alert From Residual Risk Reduction Initiative ( R3i ): 19:00 CST Sunday 9 November 2008
New Orleans, Louisiana, November 7 ( PRN/ots ) - - Residual Vascular Risk Reduction: The Global Call to Action - Announcement of the Launch of the Residual Risk Reduction Initiative: R3i KEY FACTS: Residual Risk Reduction Initiative ( R3i ) calls for action to reduce the (...) |
| 2010-06-21: |
Stallergenes: Staloral( R ) Mites 300 Clinical Study in China: Efficacy is Demonstrated
Antony, France, June 21, 2010 ( PRN/ots ) - Stallergenes S.A. announces the results of a phase III clinical trial ( VO55.06 ) conducted in China aimed at assessing the efficacy and safety of sublingual immunotherapy ( Staloral( R ) mites 300 ) in adult patients suffering from asthma triggered by house (...) |
| 2008-06-02: |
Bimatoprost / Timolol Fixed Combination Therapy Demonstrates Significantly Better IOP Control Over 12 Hours Compared to Latanoprost / Timolol Combination
Berlin, Germany ( PRN/ots ) - - First Crossover Study to Compare Fixed Combination Therapies Presented at EGS Greater intra - ocular pressure ( IOP ) lowering benefit can be achieved for glaucoma patients treated with a fixed combination of bimatoprost and timolol ( Ganfort( R ), Allergan ), new data presented today (...) |
| 2008-08-29: |
INTELENCE( TM ) ( Etravirine ) Receives Marketing Authorisation in the European Union for HIV Combination Therapy
Cork, Ireland ( PRN/ots ) - - INTELENCE is the First NNRTI to Show Antiviral Activity in Patients With NNRTI - Resistant Virus The European Medicines Agency ( EMEA ) has granted marketing authorisation for the anti - HIV medication INTELENCE( TM ) ( etravirine ). INTELENCE is a next generation non - nucleoside (...) |
| 2004-08-31: |
Data on Thelin Presented at the European Society of Cardiology Annual Congress
Houston ( PRN/ots ) - - Abstract Presented on Extension Data From STRIDE - 1 Trial in Pulmonary Arterial Hypertension Encysive Pharmaceuticals ( Nasdaq: ENCY ) today announced the presentation of data from a clinical study of Thelin( TM ) ( sitaxsentan ) in pulmonary arterial hypertension ( PAH ), at the European Society of (...) |
| 2007-05-15: |
Eisai Signs Exclusive Agreement to Commercialize NeuroBloc( R ) for Europe
Tokyo ( PRN/ots ) - Eisai Co., Ltd. ( Headquarters: Tokyo, President & CEO: Haruo Naito ) announced that the company has signed on May 14, 2007 ( the U.S. Eastern Time ) the exclusive agreement with Solstice Neurosciences, Inc. ( Headquarters: Pennsylvania, U.S., President & CEO: Shawn Patrick O'Brien ) for (...) |
| 2007-11-15: |
EFIC - Grunenthal Grant 2007: The new generation of pain researchers
Aachen, Germany ( na Originaltextservice ) - - Cross reference: Picture is available at http://www.presseportal.de/galerie.htx?type=obs - Today the European Federation of Chapters of the International Association for the Study of Pain ( EFIC ) and the pharmaceutical company Grunenthal GmbH award five (...) |
| 2007-03-27: |
Isotechnika's Independent Data Monitoring Committee Conducts Review of Phase 2b Kidney Transplant Trial
Edmonton ( PRN/ots ) - - Company Set to Host Evening Symposium at ATC Isotechnika Inc. announced today that an independent data monitoring committee ( DMC ) has met and reviewed the interim data from the Phase 2b kidney transplant ( PROMISE ) trial. The review included 3 month (...) |
| 2006-05-18: |
Invitation to the International Press Conference of the 11th Congress of the European Hematology Association
Rotterdam, Netherlands ( PRN/ots ) - - RAI CONVENTION CENTRE, AMSTERDAM Presentation of results of groundbreaking hematological research in the fields of donor stem - cell transplantation and thrombosis The 11th Congress of the European Hematology Association ( EHA ) is being held from June 15 to (...) |
| 2009-04-24: |
Roche Announces Collaboration to Investigate New Treatment Strategy With Tarceva in Lung Cancer
Basel, Switzerland ( PRN/ots ) - - New Phase III Study Will Evaluate if Tarceva is Superior to Traditional Chemotherapy in First Line Treatment of key Group of Patients Roche and the Spanish Lung Cancer Group ( SLCG ) today announced their collaboration on the first phase (...) |
| 2008-04-16: |
European Regulatory Agency Grants Orphan Status to Morphotek( R )'s Farletuzumab and MORAb - 009
Exton, Pennsylvania ( PRN/ots ) - - Upon Marketing Authorization Orphan Status Would Provide for Ten Years of Market Exclusivity in the European Union for Both Investigational Treatments Morphotek( R ), Inc., a subsidiary of Eisai Corporation of North America, announced today that the European Commission has (...) |
| 2009-02-18: |
Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
Lyon, France ( PRN/ots ) - - Global Clinical Study Program Across Dengue Endemic Regions in Latin America and Asia Sanofi Pasteur, the vaccines division of sanofi - aventis Group ( EURONEXT : SAN and NYSE : SNY ), announced today that its investigational tetravalent dengue vaccine is entering into (...) |
| 2010-01-25: |
AMP Supports the Creation of a National Immunization Technical Advisory Group in Côte d'Ivoire
Paris ( PRN/ots ) - On January 15, the Minister of Health and Hygiene of Côte d'Ivoire, Dr. Rémi Allah Kouadio, presided over a ceremony to mark the launch of a National Immunization Technical Advisory Group ( NITAG ) named "Côte d'Ivoire National Committee of Independent Experts for (...) |
| 2010-06-19: |
/OFF HOLD OFF HOLD OFF HOLD - - Servier/
Rome, June 19, 2010 ( PRN/ots ) - /OFF HOLD OFF HOLD OFF HOLD - Servier, PIV395527 The following release: "Protelos( R ) ( Strontium Ranelate ) Builds Stronger Bone Compared to Bisphosphonates" is now OFF HOLD. Distribution time: 19 Jun 2010 08:15 GMT The osteoporosis treatment Protelos( R ) (...) |
| 2005-06-27: |
Tarceva Receives Positive Opinion in EU for the Treatment of Patients With Lung Cancer
Basel, Switzerland ( PRN/ots ) - Roche announced today that its innovative, oral cancer medicine Tarceva ( erlotinib ) has received a positive recommendation from the European Committee for Medicinal Products for Human Use ( CHMP ) for the treatment of non - small cell lung cancer, the most common form (...) |
| 2005-04-21: |
Genizon Biosciences Announces Major Milestone in Identifying Genes Involved in Psoriasis
Montreal, Canada ( PRN/ots ) - Genizon BioSciences today announced the confirmation of a previously reported disease - gene location, PSORS1, as well as the identification of more than 10 new regions strongly associated with psoriasis, each containing only a limited number of genes. The company will (...) |
| 2008-05-14: |
XIENCE( TM ) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
Barcelona, Spain ( PRN/ots ) - - Data from SPIRIT II and III Clinical Trials Also Show Improvement in Vessel Renarrowing with XIENCE V Compared to TAXUS in Patients with Small Vessels Data presented today from an independent pooled subset analysis of Abbott's SPIRIT II (...) |
| 2009-04-17: |
New Partnerships Added to World Federation of Hemophilia Twinning Program
Collegeville, Pennsylvania ( PRN/ots ) - - Wyeth and Advocacy Community Mark Continued Commitment to Patient Care on World Hemophilia Day In honor of the twentieth Anniversary of World Hemophilia Day, Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), together with the World Federation of (...) |
| 2005-10-01: |
Quintiles Completes Agreement With Aptuit
Research Triangle Park, North Carolina ( PRN/ots ) - Quintiles Transnational Corp. today announced the completion of the previously announced agreement with Aptuit, Inc., to enter a strategic partnership. Aptuit has acquired three Quintiles business units - Preclinical Services, Pharmaceutical Sciences and Clinical Trial Supplies - for approximately (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
